National Cancer Institute Home at the National Institutes of Health | www.cancer.gov

Publication Abstract

Authors: Tien YY, Link BK, Brooks JM, Wright K, Chrischilles E

Title: Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Regimens without Anthracyclines are Common and Not Futile.

Journal: Leuk Lymphoma :-

Date: 2014 Mar 14

Abstract: Abstract Anthracycline-containing regimens (ACR) are recommended for DLBCL patients. However, over 40% of elderly patients do not receive ACR, possibly due to expected toxicities. We characterized treatment choices and compared the 3-year overall survival rates (OS) of 8,262 Medicare beneficiaries diagnosed with DLBCL in 2000-2006 identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. Of the cohort, 45% had ACR with rituximab (ACR-R), 13% had ACR without rituximab, 6% had non-ACR with rituximab (non-ACR-R), 4% had rituximab monotherapy, 3% had non-ACR, and 29% had no systemic therapy. Patients not receiving ACR were older and/or had more comorbidities. The unadjusted OS were highest in ACR-R (65%), followed by ACR without rituximab (55%) and non-ACR-R (44%). After adjusting patient covariates, ACR-R had the best survival (63%). However, OS was comparable between non-ACR-R (52%) and ACR without rituximab (52%). Non-ACR-R could be considered for patients who are poor candidates for ACR.

Last Modified: 03 Sep 2013